Organization Overview
Historical Acquisition Tree
Alternative names
Key: China National Biotec Group Co., Ltd (21) Acquired (2)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (5 trials)
bivalent oral polio vaccine (bopv), type 1 and type 3 (3 trials)
hepatitis a (live) vaccine (1 trial)
hepatitis a vaccine, inactivated (vaqta) (2 trials)
inactivated covid-19 vaccine (6 trials)
Key: China National Biotec Group Co., Ltd (5) Acquired (2)
Key: China National Biotec Group Co., Ltd (2) Acquired (5)
Breast Neoplasms (Phase 3)
Caliciviridae Infections (Phase 1)
Chickenpox (Phase 4)
Enterovirus Infections (Phase 4)
Foot-and-Mouth Disease (Phase 4)
Gastroenteritis (Phase 1)
Hand, Foot and Mouth Disease (Phase 4)
Hepatitis (Phase 4)
Hepatitis A (Phase 4)
Herpes Zoster (Phase 4)
Influenza, Human (Phase 4)
Influenza in Birds (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Meningitis (Phase 1)
Meningitis, Meningococcal (Phase 1)
Migraine Disorders (Phase 3)
Mouth Diseases (Phase 4)
Muscle Spasticity (Phase 3)
Plague (Phase 2)
Pneumococcal Infections (Phase 4)
Pneumonia (Phase 4)
Pneumonia, Pneumococcal (Phase 4)
Poliomyelitis (Phase 4)
Stroke (Phase 3)
Urinary Bladder, Overactive (Phase 3)
Virus Diseases (Phase 3)